Mumbai, June 22, 2017: Pharma Major Lupin Limited (Lupin) announced today the launch of its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream
USP, 0.25% having received an approval from the United States Food and Drug Administration (FDA) earlier.
Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% are the AB rated generic equivalent of Taro Pharmaceuticals North America, Inc’s Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc’s (collectively Taro) Topicort® Cream, 0.25%. Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topicort® LP Emollient Cream and Topicort® Cream had combined US sales of USD 38 million (IMS MAT April 2017).
Corporate Comm India(CCI Newswire)
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…